DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis

Information source: Addis Ababa University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schistosomiasis; Liver Fibrosis; Periportal Fibrosis; Oxidative Stress

Intervention: Praziquantel+antioxidant suppl (Dietary Supplement); Praziquantel + placebo 2mths then antioxidant for 10 mths (Other); Praziquantel therapy and placebo as supplement (Dietary Supplement); Praziquantel+antioxidant (Dietary Supplement)

Phase: N/A

Status: Recruiting

Sponsored by: Addis Ababa University

Official(s) and/or principal investigator(s):
Nega Berhe, MD, PhD, Principal Investigator, Affiliation: Aklilu Lemma Institute of Pathobiology, Addis Ababa University
Svein G Gundersen, MD PhD, Study Director, Affiliation: Sorlandet Hospital HF, Box 416, 4604 Kristiansand - Norway
Bjørn Myrvang, MD, PhD, Study Chair, Affiliation: Ullevål University Hospital, Department of Infectious Diseases, Centre for Imported and Tropical Diseases, 0407 Oslo
Rune Blomhoff, MSc, PhD, Principal Investigator, Affiliation: Institute for Basic Medical Sciences, Department of Nutrition, University of Oslo, P.O.box 1046, N-0316 Oslo, Norway

Overall contact:
Nega Berhe, MD, PHD, Phone: 00251-911-408340, Email: nega_berhe@yahoo.com

Summary

Liver fibrosis is the most serious complication of schistosomiasis mansoni. However only limited proportion of subjects with infection develop this pathology and there is limited knowledge on risk factors for the differential morbidity patterns observed in endemic communities. Our preliminary cross-sectional study indicated that serum levels of antioxidants may be related with the development of fibrosis. The present project is a randomised double blinded placebo controlled prospective study investigating the role of food based antioxidant supplements on the outcome of anti-schistosomal chemotherapy with regards to the extent of fibrosis reversal.

Clinical Details

Official title: Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Effect of antioxidant supplement on fibrosis reversal following praziquantel therapy

Secondary outcome: Time required for the reversal of schistosomal periportal fibrosis

Detailed description: Schistosomiasis is the second leading parasitic disease worldwide, after malaria. Liver fibrosis is the most serious complication of schistosomiasis mansoni which can lead to reduced work capacity and early death in endemic countries. There is, however, limited knowledge on the development of liver fibrosis and the differential patterns morbidity observed in endemic communities. Our preliminary cross-sectional study in Ethiopia seems to indicate that serum levels of antioxidants may influence the development of fibrosis. The present project is a translational study combining basic antioxidant laboratory work with is a randomised double blinded placebo controlled prospective study in endemic areas in Ethiopia, investigating the role of food based antioxidant supplements on the outcome of anti-schistosomal chemotherapy with regards to the extent of fibrosis reversal. In addition, analysis of dietary intakes of antioxidants among communities with comparable levels of S. mansoni infection but with differing levels of schistosomal periportal fibrosis will be undertaken to compare serum levels of antioxidants and prevalence of liver fibrosis. Furthermore we plan to assess development of schistosomal peri-portal fibrosis in a cohort of students established 9 years back who had comparable levels of community prevalence of schistosomiasis but with differing access to fruits and vegetables. Research on this topic has a high priority globally which is in line with the millennium development goals. Knowledge in this field will also add to our understanding of fibrosis development in general and to the efficacy of clinical treatment of schistosomiasis in particular.

Eligibility

Minimum age: 5 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects with schistosomal periportal fibrosis will be eligible for the study

Exclusion Criteria:

- Subjects with acute malaria, tuberculosis or other chronic diseases such as diabetes

mellitus, cardiovascular disease or cancer will be excluded from the study.

Locations and Contacts

Nega Berhe, MD, PHD, Phone: 00251-911-408340, Email: nega_berhe@yahoo.com

Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa 1176, Ethiopia; Recruiting
Nega Berhe, Md PhD, Phone: 00251-911-408340, Email: nega_berhe@yahoo.com
Nega Berhe, MD, PhD, Principal Investigator
Additional Information

Financial support for the research project was obtained from Ulleval hospital, Centre for Imported and Tropical Diseases

Related publications:

Berhe N, Halvorsen BL, Gundersen TE, Myrvang B, Gundersen SG, Blomhoff R. Reduced serum concentrations of retinol and alpha-tocopherol and high concentrations of hydroperoxides are associated with community levels of S. mansoni infection and schistosomal periportal fibrosis in Ethiopian school children. Am J Trop Med Hyg. 2007 May;76(5):943-9.

El-Sokkary GH, Omar HM, Hassanein AF, Cuzzocrea S, Reiter RJ. Melatonin reduces oxidative damage and increases survival of mice infected with Schistosoma mansoni. Free Radic Biol Med. 2002 Feb 15;32(4):319-32.

Berhe N, Myrvang B, Gundersen SG. Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia. Am J Trop Med Hyg. 2008 Feb;78(2):228-34.

Karlsen A, Paur I, Bøhn SK, Sakhi AK, Borge GI, Serafini M, Erlund I, Laake P, Tonstad S, Blomhoff R. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur J Nutr. 2010 Sep;49(6):345-55. doi: 10.1007/s00394-010-0092-0. Epub 2010 Feb 2.

Paur I, Austenaa LM, Blomhoff R. Extracts of dietary plants are efficient modulators of nuclear factor kappa B. Food Chem Toxicol. 2008 Apr;46(4):1288-97. Epub 2007 Nov 5.

Blomhoff R. Dietary antioxidants and cardiovascular disease. Curr Opin Lipidol. 2005 Feb;16(1):47-54. Review.

Eboumbou C, Steghens JP, Abdallahi OM, Mirghani A, Gallian P, van Kappel A, Qurashi A, Gharib B, De Reggi M. Circulating markers of oxidative stress and liver fibrosis in Sudanese subjects at risk of schistosomiasis and hepatitis. Acta Trop. 2005 May;94(2):99-106. Epub 2005 Apr 7.

Halliwell B. The antioxidant paradox. Lancet. 2000 Apr 1;355(9210):1179-80. Review.

Starting date: January 2010
Last updated: December 14, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017